Brain Mapping Instruments Market Size, Share & Trends Analysis Report By Product (Computed Axial Tomography (CAT), Positron Emission Tomography (PET), Functional MRI (fMRI)), By Region, And Segment Forecasts, 2024 - 2030

Brain Mapping Instruments Market Trends

The global brain mapping instruments market size was valued at USD 1.96 billion in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2030. The market is driven by increasing health concerns, the growing accessibility and use of newly developed technologies in the healthcare industry, and the growing predominance of neurological disorders in multiple regions. Moreover, the medical devices industry is anticipated to experience faster growth in using brain-mapping tools due to the increasing prevalence of neurological disorders, presenting an opportunity for the brain mapping instruments industry to expand.

The rise in hospital admissions and new product launches by major market players has accelerated the growth of the brain mapping instruments market. According to the American Heart Association (AHA) statistics released in 2024, there are about 5,129 community hospitals run by state and local governments, including 1,219 investor-owned community hospitals in the U.S. With the unceasing increase in demand for advanced diagnostic tools, a large number of hospitals require brain-mapping instruments, which is anticipated to fuel the market growth. Additionally, rising technological advancements in the products enhance the diagnosis of diseases and support market growth.

In recent years, there has been a notable rise in the global occurrence and frequency of neurological conditions such as Parkinson's, dementia, Huntington's disease, epilepsy, stroke, multiple sclerosis (MS), and cerebral palsy (CP); therefore, brain disorders have become one of the significant health issues that need continuous diagnosis, care and treatments backed by innovative technology and trained professionals. According to the World Health Organization 2023 report, at present, there are over 55 million individuals globally who have dementia, with a majority of over 60% residing in low- and middle-income countries. In addition, nearly 10 million cases occur annually. As per the same report, a range of illnesses and traumas that influence the brain cause dementia. Alzheimer's disease is the most prevalent type of dementia and is anticipated to account for 60-70% of cases.

Product Insights

Computed Axial Tomography (CAT) products dominated the market and accounted for a revenue share of 20.5% in 2023. Healthcare professionals often conduct CAT scans to visualize the internal anatomy of the human body and facilitate precise diagnosis and treatment. The growth of this segment is driven by its benefits as it aids physicians in visualizing tiny nodules and tumors, which is impossible through regular X-rays. In addition, it produces three-dimensional visuals of the internal body organs.

Electroencephalography (EEG) is expected to experience the fastest growth over the forecast period. The market is driven by its features, such as its ability to identify brain conditions such as seizures and epilepsy using diagnostic imaging methods. A diagnostic technique aids in identifying alterations in the electrical patterns of the brain. Therefore, the rising integration of technological advancements is enhancing the features of these instruments, fueling market expansion.

Regional Insights

North America brain mapping instruments market dominated the global industry with a revenue share of 30.9% in 2023. The market growth is primarily driven by the growing adoption of technological advancements, increasing prevalence of neurological diseases such as Alzheimer's disease (AD), and the improved healthcare infrastructure in the U.S. According to the American Association, 7 million individuals in America currently are suffering from Alzheimer's. It is estimated that by 2050, the number can increase to almost 13 million. The healthcare expenses and long-term care costs for individuals with dementia are estimated to reach USD 360 billion in 2024 and USD 1 trillion by 2050.

U.S. Brain Mapping Instruments Market Trends

The U.S. brain mapping instruments market dominated the regional industry in 2023 due to the presence of prominent companies in the nation and the growing adoption of technological advances in the healthcare industry. In addition, the U.S. is continuously investing in healthcare expenditures, public health activities, and other health-related investments. These factors are contributing to the demand for enhanced healthcare infrastructure, including brain-mapping instruments.

Europe Brain Mapping Instruments Market Trends

Europe brain mapping instrument market was identified as a lucrative region in 2023. Rising investment in launching new medical products in the region is driving market growth. For instance, in November 2023, Germitec and the European Investment Bank (EIB) agreed to provide approximately USD 27 million in funding for the creation and market launch of innovative medical products. This agreement was made feasible with the assistance of the InvestEU initiative, which aims to generate investment of over USD 410.78 billion within the duration from 2021 to 2027. In addition, growing health concerns and the occurrence of brain diseases are anticipated to drive market growth during the forecast period.

The UK brain mapping instruments market is expected to grow rapidly in the coming years due to the highly non-invasive nature of brain mapping instruments such as instruments Magnetic Resonance Imaging (MRI), Magnetoencephalography (MEG), Optically Pumped Magnetometers (OPM), and Electroencephalography (EEG). Moreover, continuous investments in research & development activities in the nation result in new product development to cater to the evolving healthcare industry. These high resonance imaging techniques aid physicians in quickly detecting and visualizing tiny tumors and brain diseases, promoting maximum adoption of brain mapping technologies.

Asia Pacific Brain Mapping Instruments Market Trends

Asia Pacific brain mapping instruments market is anticipated to witness significant growth during 2024 to 2030. The prominent market in the region includes countries such as Japan, China, India, Australia, South Korea, and Thailand. The rising population and increasing adoption of technological advancements in the region are expected to drive market expansion. According to a study published by the National Center of Biotechnology Information, Asia has the fastest-growing population of aging people. In 2023, Japan was considered a super-aging nation, with an estimated 6.5 to 7 million people expected to have Alzheimer's disease by 2025 and 8.5 to 11.5 million by 2060. The rising cases of brain diseases in the region are driving the market expansion during the forecast period.

The brain mapping instruments market in China held a substantial revenue share in 2023 owing to the rising prevalence of dementia and AD in older people. In China, the prevalence of dementia was estimated to be 6.0% overall, with specific rates of 3.9% for AD and 0.5% for other dementias in individuals aged 60 years or older. This market is primarily driven by growing need for advanced diagnosis techniques in the country, increasing availability of innovation-based equipment, increasing cases of chronic diseases and enhancements in healthcare infrastructure aimed to offering better care and treatments.

Key Brain Mapping Instruments Company Insights:

Some of the key companies in the brain mapping instruments market include Medtronic, General Electric Company, Koninklijke Philips N.V., Siemens Healthcare Private Limited, Advanced Brain Monitoring, Inc., and others. The key market participants in the industry are adopting different strategies to enhance market share that includes collaboration with other companies, improved R & D effort, geographical expansions, adoption and inclusion of advanced technology in product portfolios.

• Medtronic, a global healthcare technology company, specializes in manufacturing and developing medical devices and therapies. Its neuroscience portfolio includes advanced brain mapping and modulation systems, such as Deep Brain Stimulation (DBS), spinal cord neurostimulation systems, spine robotics, and others.

• GE Healthcare, a division of General Electric Company, offers advanced brain mapping instruments and technologies used in various neurological treatments and diagnostics. The company’s portfolio includes Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), and other instruments and services for these instruments.

Recent Developments

• In January 2024, Medtronic plc announced that the U.S. Food and Drug Administration (FDA) approved the Percept RC Deep Brain Stimulation (DBS) system. With this addition, the company expands its Medtronic Percept portfolio with a rechargeable neurostimulator, which also features BrainSense technology†, the Percept PC neurostimulator, and SenSight directional leads.

• In July 2024, Brain Products GmbH announced the release of BrainVision Analyser 2.3.0.8301, software for processing and analyzing electroencephalogram (EEG) and Enterprise resource planning (ERP) data. The software can generate high-quality scientific output, supports over 50 data formats, includes a bidirectional connection to MATLAB, and provides scientific and software assistance.

Brain Mapping Instruments Market Report Scope

Global Brain Mapping Instruments Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the brain mapping instruments market report based on product and region.

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Computed Axial Tomography (CAT)

  • Positron Emission Tomography (PET)

  • Electroencephalography (EEG)

  • Magnetoencephalography

  • Functional MRI (fMRI)

  • Functional Near-Infrared Spectroscopy (fNIRS)

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • UAE

    • South Africa

    • Kuwait